Torrent Pharmaceuticals Initiates Voluntary Recall for Select Batches of Semalix Injection Pens
Torrent Pharmaceuticals Limited has announced that it is implementing a voluntary recall as a precautionary measure for specific batches of Semalix injection disposable pens. The action follows a product recall notification received from Dr. Reddy's Laboratories Ltd., Hyderabad, which initiated a technical evaluation process.The move to recall the select batches was taken proactively by Torrent Pharmaceuticals, emphasizing patient safety as a paramount concern.
According to the company statement, there is no risk to patients currently receiving treatment with these specific products. Furthermore, Torrent assured that all other Stock Keeping Units (SKUs) of Semaglutide being sold by the company, including its oral formulations, remain completely unaffected by this recall.
The recall specifically concerns certain batches of Semalix injection disposable pens, which were manufactured by Dr. Reddy's Laboratories Ltd.
Torrent Pharmaceuticals detailed the affected and unaffected products in its update:
| Category | Product Name (mg) | Manufacturing details / Status |
|---|---|---|
| Affected Products | Semalix Injection 2 mg & 4 mg | Select batches manufactured by Dr. Reddy's Laboratories Ltd. |
| Unaffected SKUs | Semalix tablet 3 mg, 7 mg, 14 mg | Manufactured by Torrent |
| Unaffected SKUs | Sembolic tablet 3 mg, 7 mg, 14 mg | Manufactured by Torrent |
| Unaffected SKUs | Semalix injection 8 mg | Manufactured by MSN Laboratories |
| Unaffected SKUs | Sembolic re-usable injection | Manufactured by Zydus Lifesciences Ltd. |
TORNTPHARM Stock Price Movement
Today, Torrent Pharmaceuticals Limited saw its stock price climb by 0.46%, settling at ₹4898.2 in post-market trading after a positive session. The equity demonstrated steady interest throughout the day, recording a total traded volume of 460,740 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.